Cyclerion Therapeutics 경영진

경영진 기준 점검 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Regina Graul

최고경영자

US$572.2k

총 보수

CEO 급여 비율	73.41%
CEO 재임 기간	2.4yrs
CEO 지분 보유율	1.3%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	1.8yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Oct 06

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distressed company. As a result, the company is one to monitor over the next few months and wait to potentially buy the stock after new clinical data is reported.

Seeking Alpha • Jun 21

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

After two candidate failures over the past two years, Cyclerion Therapeutics, Inc. is pinning its hopes on CNS therapy CY6463. The soluble guanylate cyclase modulator is currently undergoing mid-stage evaluation for one CNS indication and should enter a Phase 2 study for another in 2021. With a small market cap and no clinical data due until YE21, yet significant insider buying from the CEO, this busted IPO merited a deeper dive. A full investment analysis is provided in the paragraphs below.

분석 기사 • Mar 09

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

분석 기사 • Jan 28

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

A look at the shareholders of Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) can tell us which group is most powerful...

분석 기사 • Dec 20

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

The last three months have been tough on Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) shareholders, who have seen the...

CEO 보수 분석

Regina Graul의 보수는 Cyclerion Therapeutics의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$5m
Dec 31 2025	US$572k	US$420k	-US$4m
Sep 30 2025	n/a	n/a	-US$2m
Jun 30 2025	n/a	n/a	-US$2m
Mar 31 2025	n/a	n/a	-US$3m
Dec 31 2024	US$875k	US$391k	-US$3m
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$496k	US$31k	-US$13m

보상 대 시장: Regina의 총 보수(USD572.15K)는 US 시장에서 비슷한 규모 기업의 평균(USD630.36K) 수준입니다.

보상과 수익: Regina의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Regina Graul (47 yo)

2.4yrs

재임 기간

US$572,153

보수

Dr. Regina M. Graul, Ph.D. is President of Cyclerion Therapeutics, Inc. from December 01, 2023 and serves as its Chief Executive Officer and Director since August 2024. Dr. Graul joined Cyclerion on Decemb...

이사회 구성원

이름	직위	재임 기간	보수	지분
Regina Graul	CEO, President & Director	1.8yrs	US$572.15k	1.32% $ 176.3k
Lawrence Olanoff	Member of Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Peter Hecht	Director	7.1yrs	데이터 없음	13.23% $ 1.8m
Errol De Souza	Independent Chairman	5.1yrs	데이터 없음	1.18% $ 158.0k
Steven Hyman	Independent Director	3.8yrs	데이터 없음	0.47% $ 63.2k
Michael Higgins	Independent Director	2.5yrs	데이터 없음	0.73% $ 97.1k
Husseini Manji	Member of Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Linda Carpenter	Member of Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Dina Katabi	Independent Director	2.4yrs	데이터 없음	0.47% $ 63.2k
Yuriy Bronshteyn	Member of Clinical Advisory Board	less than a year	데이터 없음	데이터 없음
Laeben Lester	Member of Clinical Advisory Board	less than a year	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

64.5yo

평균 나이

경험이 풍부한 이사회: CYCN의 이사회는 경험이 부족한 것으로 간주됩니다(평균 재임 1.8 년) — 신규 이사회일 가능성이 있습니다.

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/22 17:58
종가	2026/05/22 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cyclerion Therapeutics, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Pete Stavropoulos	Cantor Fitzgerald & Co.
Joon So Lee	Truist Securities
David Bautz	Zacks Small-Cap Research

Cyclerion Therapeutics 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

High number of new and inexperienced directors

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 16, 2025

Cyclerion Therapeutics, Inc. Announces Promotion of Regina Graul to Chief Executive Officer

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Cyclerion Therapeutics, Inc. Appoints Regina Graul as President

Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments

Recent updates

First quarter 2026 earnings released: US$0.76 loss per share (vs US$0.56 loss in 1Q 2025)

New major risk - Financial position

Korsana Biosciences, Inc. entered into a definitive merger agreement to acquire Cyclerion Therapeutics, Inc. (NasdaqCM:CYCN) for approximately $270 million in a reverse merger transaction.

High number of new and inexperienced directors

Cyclerion Therapeutics, Inc. Receives Positive Written Regulatory Feedback and Responses from the FDA on CYC-126's Phase 2 POC study in TRD and Its Path to Potential Regulatory Approval

New major risk - Revenue and earnings growth

Cyclerion Therapeutics, Inc. Announces Progress Toward Initiating Phase 2 Proof-Of-Concept Study for CYC-126 in Treatment-Resistant Depression

New major risk - Shareholder dilution

New major risk - Financial position

New minor risk - Shareholder dilution

Cyclerion Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

New major risk - Financial position

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 16, 2025

Cyclerion Therapeutics, Inc. announced that it has received $1.374995 million in funding from J. Wood Capital Advisors LLC, Polaris Founders Capital and other investors

Cyclerion Therapeutics, Inc. Announces Promotion of Regina Graul to Chief Executive Officer

Cyclerion Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Cyclerion Therapeutics, Inc. Appoints Regina Graul as President

Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments

Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director

Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer

New major risk - Financial position

First half 2023 earnings released: US$5.00 loss per share (vs US$12.14 loss in 1H 2022)

New major risk - Market cap size

Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding

High number of new and inexperienced directors

J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.01 loss per share (vs US$1.32 loss in FY 2021)

Cyclerion Therapeutics Announces an Extended Listing Compliance Period

Price target decreased to US$4.00

Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021)

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Consensus revenue estimates fall by 54%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia

Cyclerion Therapeutics, Inc. Announces Appointment of Steven E. Hyman, M.D., to its Board of Directors

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Cyclerion Therapeutics, Inc. Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for Cy6463 in Melas Patients At Umdf Mitochondrial Medicine 2022 Symposium

Cyclerion Therapeutics Receives a Deficiency Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

High number of new directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Progress

Price target increased to US$10.50

High number of new directors

Consensus revenue estimates fall by 49%

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Full year 2021 earnings: EPS and revenues miss analyst expectations

Cyclerion Therapeutics, Inc. Announces CY6463 Clinical Pipeline Updates

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.59 loss in 3Q 2020)

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Cyclerion Therapeutics, Inc Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Independent Director Kevin Churchwell has left the company

Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.70 loss in 2Q 2020)

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021

Cyclerion Therapeutics, Inc.(NasdaqGS:CYCN) dropped from Russell 3000E Value Index

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Cyclerion Therapeutics, Inc. announced that it has received $17.896283 million in funding from EcoR1 Capital, LLC, Slate Path Capital LP, MFN Partners Management, LP, The Invus Group, LLC, Lincoln Park Capital, LLC, Polaris Partners

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

CEO & Director recently bought US$1.7m worth of stock

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2020)

Cyclerion Therapeutics, Inc. Provides Clinical Updates for its CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 in Alzheimer's Disease with Vascular Pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes

Cyclerion Therapeutics, Inc. Announces Departure of Christopher Wright as Chief Medical Officer

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Full year 2020 earnings released: US$2.56 loss per share (vs US$4.49 loss in FY 2019)

Earnings beat expectations